5-Amino-1MQ: NNMT Inhibition and the State of a Very Thin Literature

Target and rationale

NNMT catalyses the transfer of a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. Nicotinamide is a salvage-pathway precursor to NAD+, so the proposed rationale is that inhibiting NNMT preserves the nicotinamide pool and raises NAD+ availability, while also reducing consumption of the cell's methyl-donor supply.

NNMT is expressed at high levels in adipose tissue and liver, and its expression is reported to rise in obesity and in several tumour types. That expression pattern, rather than any direct result with this compound, is what drives interest in it.

Note carefully what this means for interpretation: almost everything written about 5-Amino-1MQ is an inference from NNMT biology, not an observation of the compound. The enzyme is well studied. The inhibitor is not.

What the three indexed papers actually study

Akar et al. (J Obstet Gynaecol, 2021) report anti-proliferative activity of an NNMT inhibitor in HeLa cells. This is a cell-line study, not a metabolic one.

Dimet-Wiley et al. (Sci Rep, 2022) examine NNMT inhibition combined with caloric restriction in diet-induced obese mice, with the microbiome as the primary readout.

Yang et al. (J Immunother Cancer, 2024) study NNMT in cancer-associated fibroblasts in urothelial bladder cancer, where the enzyme drives tumour progression and immunotherapy resistance.

None of the three is a characterisation of 5-Amino-1MQ as a compound: no pharmacokinetics, no dose-response in a metabolic model, no independent replication of any endpoint.

Handling and interpretation

As a small quinolinium salt rather than a peptide, its stability profile differs from the rest of this catalogue, and peptide-handling conventions do not transfer directly.

Any experimental design using this compound should treat the NNMT literature as background and the compound literature as essentially absent. Include vehicle and enzyme-activity controls rather than assuming target engagement from dose alone.